{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:18:38Z","timestamp":1793449118749,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.tjpad.2025.100473","type":"journal-article","created":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T01:33:15Z","timestamp":1767231195000},"page":"100473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety profiles of lecanemab: A systematic review and meta-analysis of randomized controlled trials and real-world evidence"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8572-3782","authenticated-orcid":false,"given":"Lin","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangxue","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjiao","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0080-9102","authenticated-orcid":false,"given":"Reema","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhui","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjpad.2025.100473_bib0001","author":"Gauthier","year":"2022","journal-title":"World Alzheimer Report 2022"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100473_bib0002","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1002\/alz.13809","article-title":"2024 Alzheimer's disease facts and figures","volume":"20","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100473_bib0003","doi-asserted-by":"crossref","first-page":"S569","DOI":"10.3233\/JAD-2010-100357","article-title":"Role of mitochondrial amyloid-beta in Alzheimer's disease","volume":"20","author":"Chen","year":"2010","journal-title":"J Alzheimers Dis"},{"issue":"R1","key":"10.1016\/j.tjpad.2025.100473_bib0004","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1093\/hmg\/ddq160","article-title":"Molecular mechanisms of neurodegeneration in Alzheimer's disease","volume":"19","author":"Crews","year":"2010","journal-title":"Hum Mol Genet"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100473_bib0005","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00401-012-0987-3","article-title":"Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau","volume":"123","author":"Van der Jeugd","year":"2012","journal-title":"Acta Neuropathol"},{"issue":"41","key":"10.1016\/j.tjpad.2025.100473_bib0006","doi-asserted-by":"crossref","first-page":"9917","DOI":"10.1523\/JNEUROSCI.0621-17.2017","article-title":"Inhibition of p25\/Cdk5 attenuates tauopathy in mouse and iPSC models of frontotemporal dementia","volume":"37","author":"Seo","year":"2017","journal-title":"J Neurosci"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100473_bib0007","doi-asserted-by":"crossref","first-page":"5092","DOI":"10.1096\/fj.201902230RR","article-title":"Abeta monomer induces phosphorylation of tau at ser-214 through beta2AR-PKA-JNK signaling pathway","volume":"34","author":"Wu","year":"2020","journal-title":"FASEB J"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100473_bib0008","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.2353\/ajpath.2010.100346","article-title":"Abeta accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model","volume":"177","author":"Hurtado","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.tjpad.2025.100473_bib0009","doi-asserted-by":"crossref","first-page":"p73","DOI":"10.1136\/bmj.p73","article-title":"Alzheimer\u2019s disease: FDA approves lecanemab amid cost and safety concerns","volume":"380","author":"Mahase","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.tjpad.2025.100473_bib0010","doi-asserted-by":"crossref","first-page":"p1580","DOI":"10.1136\/bmj.p1580","article-title":"Alzheimer\u2019s disease: lecanemab gets full FDA approval and black box safety warning","volume":"382","author":"Mahase","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.tjpad.2025.100473_bib0011","first-page":"q1692","article-title":"European drug agency rejects Alzheimer\u2019s drug amid debate over efficacy and safety","volume":"386","author":"Lecanemab","year":"2024","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100473_bib0012","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100473_bib0013","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.tjpad.2025.100473_bib0014","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.tjpad.2025.100473_bib0015","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100473_bib0016","first-page":"153","article-title":"How to perform a meta-analysis with R: a practical tutorial. Evid based ment health","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Nov"},{"key":"10.1016\/j.tjpad.2025.100473_bib0017","unstructured":"Team RC. The R Project for Statistical Computing. https:\/\/wwwR-projectorg. 2025."},{"issue":"1","key":"10.1016\/j.tjpad.2025.100473_bib0018","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer's disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100473_bib0019","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-a\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Therapy"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100473_bib0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"New Eng J Med"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100473_bib0021","article-title":"ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease. Article","volume":"9","author":"Honig","year":"2023","journal-title":"Alzheimers Dementia-Translat Res Clin Intervent"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100473_bib0022","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13195-025-01763-1","article-title":"Lecanemab in clinical practice: real-world outcomes in early Alzheimer\u2019s disease","volume":"17","author":"Bregman","year":"2025","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2025.100473_bib0023","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2025.1232","article-title":"Lecanemab treatment in a Specialty Memory clinic. Article; Early Access","author":"Paczynski","year":"2025","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100473_bib0024","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s00415-025-13142-9","article-title":"Monoclonal antibody administration in an academic institution and private neurological practice: a tale of two clinics. Article","volume":"272","author":"Rosenbloom","year":"2025","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100473_bib0025","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.14283\/jpad.2024.159","article-title":"Initial experience with Lecanemab and lessons learned in 71 patients in a regional medical center. Article","volume":"11","author":"Shields","year":"2024","journal-title":"Jpad-J Prevent Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100473_bib0026","article-title":"ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease","volume":"9","author":"Honig","year":"2023","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100473_bib0027","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13195-025-01763-1","article-title":"Lecanemab in clinical practice: real-world outcomes in early Alzheimer's disease. Article","volume":"17","author":"Bregman","year":"2025","journal-title":"Alzheimers Research & Therapy"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100473_bib0028","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.neuron.2017.11.013","article-title":"ApoE4 Accelerates early seeding of amyloid pathology","volume":"96","author":"Liu","year":"2017","journal-title":"Neuron"},{"issue":"7","key":"10.1016\/j.tjpad.2025.100473_bib0029","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1007\/s10571-023-01365-1","article-title":"Roles of ApoE4 on the pathogenesis in Alzheimer's disease and the potential therapeutic approaches","volume":"43","author":"Sun","year":"2023","journal-title":"Cell Mol Neurobiol"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100473_bib0030","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s43587-021-00073-z","article-title":"APOE4 accelerates advanced-stage vascular and neurodegenerative disorder in old Alzheimer's mice via cyclophilin A independently of amyloid-\u03b2","volume":"1","author":"Montagne","year":"2021","journal-title":"Nat Aging"},{"key":"10.1016\/j.tjpad.2025.100473_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2025.103805","article-title":"Blood-brain barrier permeability varies by brain region and APOE4 status and correlates with brain microstructure among high-AD risk groups","volume":"46","author":"Solders","year":"2025","journal-title":"Neuroimage Clin"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100473_bib0032","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1038\/s41598-020-59869-5","article-title":"Associations between brain inflammatory profiles and human neuropathology are altered based on apolipoprotein E \u03b54 genotype","volume":"10","author":"Friedberg","year":"2020","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100473_bib0033","article-title":"Clinical efficacy of anti-amyloid antibodies in apolipoprotein E \u03b54 homozygotes: a bayesian reanalysis of lecanemab and donanemab phase 3 results","volume":"11","author":"Teipel","year":"2025","journal-title":"Alzheimers Dement (N Y)"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100473_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100094","article-title":"Lecanemab for early Alzheimer's disease: appropriate use recommendations from the French federation of memory clinics","volume":"12","author":"Villain","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100473_bib0035","first-page":"720","article-title":"Clinical observation and nursing management of infusion-related reactions induced by lecanemab in Alzheimer disease patients","volume":"26","author":"Fan Kaiting","year":"2024","journal-title":"Adverse Drug React J"},{"key":"10.1016\/j.tjpad.2025.100473_bib0036","unstructured":"US Food & Drug Administration. FDA adverse event reporting system (FAERS) quarterly data extract files. Accessed October 17, 2025. https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files."},{"issue":"1","key":"10.1016\/j.tjpad.2025.100473_bib0037","doi-asserted-by":"crossref","first-page":"8220","DOI":"10.1038\/s41467-023-43933-5","article-title":"Fatal iatrogenic cerebral \u03b2-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's disease. Article","volume":"14","author":"Solopova","year":"2023","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100473_bib0038","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMc2215148","article-title":"Multiple cerebral hemorrhages in a patient receiving Lecanemab and treated with t-PA for stroke","volume":"388","author":"Reish","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100473_bib0039","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3233\/JAD-221305","article-title":"Neuropathology of Anti-amyloid-\u03b2 immunotherapy: a case report","volume":"93","author":"Castellani","year":"2023","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100473_bib0040","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1177\/13872877251323231","article-title":"Cost-effectiveness of diagnosing and treating patients with early Alzheimer's disease with anti-amyloid treatment in a clinical setting","volume":"104","author":"Wimo","year":"2025","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100473_bib0041","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70375","article-title":"Real-world\" eligibility for anti-amyloid treatment in a tertiary memory clinic setting","volume":"21","author":"Vigneswaran","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100473_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100102","article-title":"Patient eligibility for amyloid-targeting immunotherapies in Alzheimer's disease","volume":"12","author":"Rosen","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100473_bib0043","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16534","article-title":"Mild cognitive impairment and early Alzheimer's disease eligibility for disease modification therapies in a tertiary centre for cognitive disorders: a simultaneous real-word study on aducanumab and lecanemab","volume":"32","author":"Logroscino","year":"2025","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100473_bib0044","first-page":"2","article-title":"Assessing the preparedness of the health care system infrastructure in six European countries for an Alzheimer's treatment","volume":"8","author":"Hlavka","year":"2019","journal-title":"Rand Health Q"},{"issue":"19","key":"10.1016\/j.tjpad.2025.100473_bib0045","doi-asserted-by":"crossref","first-page":"e2102","DOI":"10.1212\/WNL.0000000000201043","article-title":"\u03b2-amyloid, tau, neurodegeneration classification and eligibility for anti-amyloid treatment in a Memory Clinic population","volume":"99","author":"Rosenberg","year":"2022","journal-title":"Neurology"},{"issue":"19","key":"10.1016\/j.tjpad.2025.100473_bib0046","doi-asserted-by":"crossref","first-page":"e1837","DOI":"10.1212\/WNL.0000000000207770","article-title":"Eligibility for anti-amyloid treatment in a population-based study of cognitive aging","volume":"101","author":"Pittock","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.tjpad.2025.100473_bib0047","doi-asserted-by":"crossref","DOI":"10.1111\/jgs.19577","article-title":"Implementation of Lecanemab for Alzheimer's Disease within the Veterans Health Administration: facilitators and barriers","author":"O'Donnell","year":"2025","journal-title":"J Am Geriatr Soc."}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725004145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725004145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:38:42Z","timestamp":1773261522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580725004145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2274580725004145"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100473","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety profiles of lecanemab: A systematic review and meta-analysis of randomized controlled trials and real-world evidence","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100473","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100473"}}